Crucell N.V. (CRXL) Signs Commercial PER.C6 License Agreement With SingVax Pte Ltd For Vaccines Against Japanese Encephalitis
10/19/2005 5:13:05 PM
LEIDEN, Netherlands, March 22, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Nasdaq:CRXL) (Euronext:CRXL) today announced the signing of a commercial PER.C6(R) license agreement with Singapore-based company SingVax Pte Ltd for the development and commercialisation of new vaccines against Japanese encephalitis.
Under the agreement, SingVax will focus on the development and commercialisation of a Japanese encephalitis vaccine for the endemic population as well as for travellers to the Asia Pacific region.
comments powered by